• Media type: E-Article
  • Title: Nutraceutical Strategies for Suppressing NLRP3 Inflammasome Activation: Pertinence to the Management of COVID-19 and Beyond
  • Contributor: McCarty, Mark F.; Iloki Assanga, Simon Bernard; Lewis Luján, Lidianys; O’Keefe, James H.; DiNicolantonio, James J.
  • imprint: MDPI AG, 2020
  • Published in: Nutrients
  • Language: English
  • DOI: 10.3390/nu13010047
  • ISSN: 2072-6643
  • Keywords: Food Science ; Nutrition and Dietetics
  • Origination:
  • Footnote:
  • Description: <jats:p>Inflammasomes are intracellular protein complexes that form in response to a variety of stress signals and that serve to catalyze the proteolytic conversion of pro-interleukin-1β and pro-interleukin-18 to active interleukin-1β and interleukin-18, central mediators of the inflammatory response; inflammasomes can also promote a type of cell death known as pyroptosis. The NLRP3 inflammasome has received the most study and plays an important pathogenic role in a vast range of pathologies associated with inflammation—including atherosclerosis, myocardial infarction, the complications of diabetes, neurological and autoimmune disorders, dry macular degeneration, gout, and the cytokine storm phase of COVID-19. A consideration of the molecular biology underlying inflammasome priming and activation enables the prediction that a range of nutraceuticals may have clinical potential for suppressing inflammasome activity—antioxidants including phycocyanobilin, phase 2 inducers, melatonin, and N-acetylcysteine, the AMPK activator berberine, glucosamine, zinc, and various nutraceuticals that support generation of hydrogen sulfide. Complex nutraceuticals or functional foods featuring a number of these agents may find utility in the prevention and control of a wide range of medical disorders.</jats:p>
  • Access State: Open Access